Colleen R. Kelly

Colleen R. Kelly

Auto-generated profile, based on publicly available information

Colleen R. Kelly

Brigham and Women’s Hospital

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
16 October 2026 in Alimentary Pharmacology & Therapeutics
Verified
Journal Article
Closed access
CKC. R. Kelly
C. R. Kelly
BKB. J. Kelly
B. J. Kelly
QWQ. Wu
Q. Wu
LLL. Laine
L. Laine
GWG. D. Wu
G. D. Wu
JLJ. D. Lewis
J. D. Lewis

22 April 2025 in Clinical Infectious Diseases
Verified
Journal Article
Closed access
JAJessica R. Allegretti
Jessica R. Allegretti
MFMonika Fischer
Monika Fischer
CKColleen R Kelly
Colleen R Kelly

24 November 2025 in Antimicrobial Stewardship & Healthcare Epidemiology
Verified
Journal Article
Open access
SGSapana R. Gupta
Sapana R. Gupta
TSTyler Selig
Tyler Selig
KEKathryn Evey
Kathryn Evey
MRMichael Rossi
Michael Rossi
ABAdam Burton
Adam Burton
CKColleen R. Kelly
Colleen R. Kelly
Introduction: Clostridioides difficile is the primary cause of healthcare-associated infectious diarrhea in hospitalized patients. The most common laboratory testing methods for C. difficile infection (CDI) are toxin detection via enzyme immunoassay (EIA) and polymerase chain reaction (PCR), which detect a toxogenic strain. This study examines the impact of Rhode Island’s largest hospital system changing from PCR-only to two-step CDI testing. Methods: A retrospective cohort study of 2,173 adult inpatients was conducted. Patients were grouped into two cohorts: those tested for toxigenic C. difficile via PCR-only (June 2019–May 2021, n = 1,194) and those tested with the two-step algorithm (June 2021–May 2023, n = 979). Cluster analysis identified patient risk groups for hypothesis generation, and complications such as death, colectomy, intensive care unit ICU transfer, and 30-day readmission were compared across these groups. Results: In the moderate-risk group, there was a significant reduction in ICU transfers and readmission rates with the two-step testing by 5% and 7%, respectively. There were no other significant differences in complications between testing groups. Anti-CDI antibiotics were discontinued in 15% ( n = 106) of EIA-negative patients in the two-step testing group. Moderate-risk patients were less likely to have treatment discontinued than severe-risk patients (OR = 2.00, p = 0.016). Discussion: The two-step testing algorithm did not negatively affect patient outcomes and led to a modest decrease in anti-CDI treatment, supporting the safety of two-step CDI testing in hospitalized patients.

6 March 2026
Verified
Book Chapter
Closed access
PDF file
CKColleen R. Kelly
Colleen R. Kelly
Clostridioides difficile infection (CDI) is a leading healthcare-associated infection, primarily affecting older adults and patients with recent antibiotic exposure. Gastroenterology (GI) and infectious disease (ID) societies have developed separate guidelines reflecting their respective focuses. This review compares recommendations from the American College of Gastroenterology (ACG), Infectious Diseases Society of America/Society for Healthcare Epidemiology of America (IDSA/SHEA), and the American Gastroenterological Association (AGA). Both ACG and IDSA/SHEA endorse multistep diagnostic algorithms combining sensitive and specific assays, though IDSA permits PCR-only testing under strict criteria. For initial CDI, vancomycin and fidaxomicin are first-line agents, with IDSA’s 2021 update prioritizing fidaxomicin for reduced recurrence. Recurrent CDI management is similar, emphasizing fidaxomicin, tapered vancomycin, and fecal microbiota transplantation (FMT) after multiple recurrences. ACG and AGA provide greater specificity for FMT use and endorse microbiota-based therapies earlier in high-risk or treatment-refractory patients. Both guidelines (e.g., ACG and IDSA/SHEA) align on definitions and treatment for severe and fulminant CDI but diverge on prophylactic vancomycin and management in inflammatory bowel disease. Overall, the recommendations are largely concordant, with GI guidelines emphasizing fecal microbiota therapies and individualized care. Trials of defined synthetic consortia of bacteria are underway and may further alter the treatment landscape. Clinical trials and experience with these agents will inform future prevention and treatment algorithms as we move toward the safest and most effective therapeutic strategies for CDI.